Advertisement

Abdominal Radiology

, Volume 42, Issue 5, pp 1583–1585 | Cite as

Frequency of high blood glucose prior to FDG PET

  • Amir H. Khandani
  • Isabel M. Bravo
  • Parth S. Patel
  • Marijana Ivanovic
  • Deepa Kirk
Article
  • 101 Downloads

Abstract

Purpose

To assess the frequency of blood glucose level higher than 150 mg/dL in non-diabetic patients presenting for FDG PET.

Methods

We reviewed the electronic medical record (EMR) of all lymphoma patients who had at least one FDG PET/CT from July 1, 2014 through June 30, 2015. We extracted the blood glucose level at the time of the FDG PET during this 1-year time period and any previous PET scans these patients had. Patients’ diabetic status was determined from EMR.

Results

One hundred seventeen patients with 574 scans were included: 91 non-diabetic with 429 scans and 26 diabetic patients with 145 scans. Blood glucose level ranged from 44 to 259 mg/dL: 44 to 144 mg/dL in non-diabetic patients and 73 to 259 mg/dL in diabetic patients. There was no non-diabetic patient with a glucose level higher than 150 mg/dL at any occasion. Only one scan was performed with 144 mg/dL of glucose. All other scans were performed with a glucose level less than 140 mg/dL. There were nine diabetic patients with glucose level less than 150 mg/dL prior to all of their scans and 17 diabetic patients with a glucose level higher than 150 mg/dL prior to PET at least on one occasion.

Conclusions

In all non-diabetic patients, blood glucose level was below the lower limit of the recommended range prior to all their FDG PET scans while this was not the case in diabetic patients. We conclude that measuring blood glucose level prior to FDG PET may be limited to diabetic patients.

Keywords

FDG PET Glucose level Diabetes 

Notes

Compliance with ethical standards

Funding

No funding was received for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Informed consent

Statement of informed consent was not applicable since the manuscript does not contain any patient data.

References

  1. 1.
    Delbeke D, Coleman RE, Guiberteau MJ, et al. (2006) Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 47:885–895PubMedGoogle Scholar
  2. 2.
    ACR–SPR Practice Parameter for Performing FDG-PET/CT in Oncology Res. 24—2012, Amended 2014 (Res. 39). http://www.acr.org
  3. 3.
    Boellaard R, Delgado-Bolton R, Oyen WJ, et al. (2015) European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354CrossRefGoogle Scholar
  4. 4.
    Graham MM, Badawi RD, Wahl RL (2011) Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med 52:311–317CrossRefGoogle Scholar
  5. 5.
    American Diabetes Association (2016) Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes. Diabetes 39(Suppl 1):S13–S22Google Scholar
  6. 6.
    Mirpour S, Meteesatien P, Khandani AH (2012) Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT? Rev Esp Med Nucl Imagen Mol 31:71–77PubMedGoogle Scholar
  7. 7.
    Hara T, Higashi T, Nakamoto Y, et al. (2009) Significance of chronic marked hyperglycemia on FDG-PET: is it really problematic for 305 clinical oncologic imaging? Ann Nucl Med 23:657–669CrossRefGoogle Scholar
  8. 8.
    Rabkin Z, Israel O, Keidar Z (2010) Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A Comparative analysis. J Nucl Med 51:1015–1120CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Amir H. Khandani
    • 1
  • Isabel M. Bravo
    • 1
  • Parth S. Patel
    • 1
  • Marijana Ivanovic
    • 1
  • Deepa Kirk
    • 2
  1. 1.Division of Nuclear Medicine, Department of RadiologyUNC School of MedicineChapel HillUSA
  2. 2.Division of Endocrinology and Metabolism, Department of MedicineUNC School of MedicineChapel HillUSA

Personalised recommendations